Medicine guide

RYSTIGGO

As listed in the register: RYSTIGGO

560 mg · solution

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Rozanolixizumab
Made by
Ucb Canada Inc

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL04AL02

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

European UnionNo exact match for this strength and form

SpainNo exact match for this strength and form

FranceNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

Details

Made byUcb Canada Inc
Active substanceRozanolixizumab
Used inCancer treatments and immune-system medicines
Strength560 mg
Formsolution
ClassificationL04AL02 · Cancer treatments and immune-system medicines
Routesubcutaneous
Dispensing (as stated by the register)PRESCRIPTION · SCHEDULE D
StatusApproved
MarketedNo — authorised but not currently marketed, according to the register
DIN02567075
DPD drug code106953

Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician

Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.

Other strengths and forms

4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.